Capella raises L11 million series A

Capella Bioscience Ltd. (London, U.K.) raised L11 million ($15.6 million) in a tranched series A round with Advent Life Sciences, Medicxi Ventures and Osage University Partners. Capella's lead program is a first-in-class antibody that inhibits an undisclosed target involved in inflammatory bowel disease (IBD). ...